A bullish thesis on Zoetis Inc. argues the animal health leader is a compelling contrarian opportunity after its stock fell more than 50% from highs, compressing its valuation to roughly 12.8 times trailing earnings versus a historical average of 36.6 times. The company generates about 70% of revenue from companion animal products including Simparica, Apoquel, and Cytopoint, while its livestock segment provides stability. The thesis contends that recent weakness in osteoarthritis treatments Librela and Solensia stems from temporary perception issues rather than permanent franchise damage, and that Zoetis is actively educating veterinarians to stabilize sales. With a cash-pay business model supporting consistent pricing power, strong free cash flow, and aggressive capital returns through dividends and buybacks, the stock could deliver nearly 100% upside if it rerates to a 25 times earnings multiple.
Zoetis IncAnalyst thesis argues stock is undervalued at 12.8x trailing earnings vs historical 36.6x, with potential to rerate to 25x, implying nearly 100% upside.